Northfield
Bile Acids in Hepatobiliary Disease
Herausgegeben:Northfield, T. C.; Ahmed, H.; Jazwari, R.; Zentler-Munro, P.
Northfield
Bile Acids in Hepatobiliary Disease
Herausgegeben:Northfield, T. C.; Ahmed, H.; Jazwari, R.; Zentler-Munro, P.
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book is the proceedings of the Falk Workshop on `Bile Acids in Hepatobiliary Disease', which took place at the Royal Society of Medicine (RSM) in London, UK, on 29-30 March 1999, and was held in association with the Section of Measurement in Medicine at the RSM. The main interest in bile acid therapy has been recently in cholestatic liver disease. The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease. Leading world experts attempt to define its mechanism of…mehr
Andere Kunden interessierten sich auch für
- PaumgartnerBile Acids and Hepatobiliary Diseases - Basic Research and Clinical Application166,99 €
- van Berge HenegouwenBiology of Bile Acids in Health and Disease125,99 €
- PaumgartnerEnterohepatic Circulation of Bile Acids and Sterol Metabolism166,99 €
- G. Paumgartner / U. Beuers (eds.)Bile Acids in Liver Diseases125,99 €
- M. Acalovschi / G. Paumgartner (Hgg.)Hepatobiliary Diseases: Cholestasis and Gallstone83,99 €
- MaternHepatobiliary Transport: From Bench to Bedside125,99 €
- J. Spic k / J.L. Boyer / T. Gilat / J. Kotrlik / Z. Marecek / G. Paumgartner (Hgg.)Diseases of the Liver and the Bile Ducts166,99 €
-
-
-
This book is the proceedings of the Falk Workshop on `Bile Acids in Hepatobiliary Disease', which took place at the Royal Society of Medicine (RSM) in London, UK, on 29-30 March 1999, and was held in association with the Section of Measurement in Medicine at the RSM.
The main interest in bile acid therapy has been recently in cholestatic liver disease. The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease. Leading world experts attempt to define its mechanism of action, and the current role of other non-surgical treatments in biliary disease. The physiology and pathogenesis of cholestatic and alcoholic liver disease and cholesterol gallstone disease is also examined.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
The main interest in bile acid therapy has been recently in cholestatic liver disease. The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease. Leading world experts attempt to define its mechanism of action, and the current role of other non-surgical treatments in biliary disease. The physiology and pathogenesis of cholestatic and alcoholic liver disease and cholesterol gallstone disease is also examined.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Falk Symposium 110a
- Verlag: Springer / Springer Netherlands
- Artikelnr. des Verlages: 978-0-7923-8755-8
- 2000.
- Seitenzahl: 364
- Erscheinungstermin: 29. Februar 2000
- Englisch
- Abmessung: 241mm x 160mm x 25mm
- Gewicht: 685g
- ISBN-13: 9780792387558
- ISBN-10: 0792387554
- Artikelnr.: 23080745
- Falk Symposium 110a
- Verlag: Springer / Springer Netherlands
- Artikelnr. des Verlages: 978-0-7923-8755-8
- 2000.
- Seitenzahl: 364
- Erscheinungstermin: 29. Februar 2000
- Englisch
- Abmessung: 241mm x 160mm x 25mm
- Gewicht: 685g
- ISBN-13: 9780792387558
- ISBN-10: 0792387554
- Artikelnr.: 23080745
Preface. List of Contributors. 1. Introduction; T.C. Northfield. Section I:
Cholestatic Liver Disease: Physiology, Pathogenesis and Epidemiology. 2.
Cellular and Molecular Mechanisms of Bile Salt Transport in Health and
Disease; J.L. Boyer. 3. Biochemical Aspects; J. Reichen. 4. Immunological
Aspects; M.F. Bassendine. Section II: Bile Acid Therapy. 5. Optimum Dose of
UDCA in Primary Biliary Cirrhosis (PBC); A. Verma. 6. Ursodeoxycholic Acid
- An Immunomodulator in Primary Biliary Cirrhosis? A.G. Lim, et al.
Section III: Clinical Trials. 7. Primary Biliary Cirrhosis: Long-Term
Management with Ursodeoxycholic Acid; J. Heathcote. 8. Management of
Patients with Primary Schlerosing Cholangitis; A. Stiehl. 9. Genetic
Aspects; R. Thompson. 10. Congenital Defects in Bile Acid Synthesis Cause A
Spectrum of Diseases Manifest as Severe Cholestasis, Neurological Disease,
and Fat-Soluble Vitamin Malabsorption; K.D.R. Setchell. 11. Cystic Fibrosis
of the Liver; C. Colombo. 12. Canalicular Secretion of Lysyl-fluorescein
Bile Acids in 17beta-estradiol Glucuronide (17betaEG) Induced Cholestasis:
Protective Effect of S-andenosyl-L-methionine (SAMe); P. Milkiewicz.
Section IV: Alcoholic and Other Liver Diseases. 13. Ethanol Metabolism; T.
Peters. 14. Alcohol Abuse and Abstinence; H. Ghodse. 15. Pathogenesis of
Alchoholic Liver Disease; C.S. Lieber. 16. Clinical Aspects of Alcoholic
Liver Disease; R. Williams. Section V: Bile Acid Therapy. 17. Effect on
Liver Function; P. Hayes. 18. Fibrosis Markers and Ursodeoxycholic Acid;
J.M.C. Stenner. 19. Urdodeoxycholic Acid for Treatment of Chronic Hepatitis
C: An `Interferon Sparing' Effect; A. Lanzini. Section VI: Cholesterol
Gallstone Disease. 20. Pathogenesis of Cholesterol Gallstone Disease: Role
of the Liver; M.C. Carey. 21. Pathogenesis of Gallstones: Events in Bile;
T. Gilat. 22. Role of the Gallbladder in the Pathogenesis of Gallstone
Disease; R.P. Jazrawi, et al. 23. The Role of the Large Intestine in
Cholesterol Gallstone Formation; K.W. Heaton. 24. The Octreotide Model;
R.H. Dowling. Section VII: Therapy. 25. Oral Bile Acid Therapy; E. Roda.
26. Cholesterol Solvents for Topical Gallstone Dissolution; U. Leuschner.
27. Mechanisms of Dissolution of Cholesterol Gallstones; H.A. Ahmed. 28.
Extracorporeal Shock-wave Lithotripsy of Gallstones; G.H. Sauter. 29.
Management of Gallstone Recurrence; T.C. Northfield. 30. Laparoscopic
Cholecystectomy; A. Johnson. 31. Comparison of UDCA With Combination
Therapy of UDCA Plus CDCA on Gallstone Dissolution: A Randomised
Multicentre Trial; M.L. Petroni. Section VIII: Other Conditions. 32. Role
of Bile Acids in Colonic Neoplasia: Experimental Animal Studies; C.A.
Einarsson. 33. Role of Bile Acids in Colonic Neoplasia &endash; Human
Studies; M. Stellini. Section IX: Chronic Pancreatitis. 34. Role of Bile
Acids in Pancratic Steatorrhea; P. Zentler-Munro. 35. Impaired Uptake of
Long-chain Fatty Acids Contributes to Fat Malabsorption in Paediatric
Patients with Cystic Fibrosis; H.J. Verkade. 36. Bile Acid Science
(Cholanology) at the Dawn of a New Millennium: Past Progress and Challenges
for the Future; A.F. Hofmann. Index.
Cholestatic Liver Disease: Physiology, Pathogenesis and Epidemiology. 2.
Cellular and Molecular Mechanisms of Bile Salt Transport in Health and
Disease; J.L. Boyer. 3. Biochemical Aspects; J. Reichen. 4. Immunological
Aspects; M.F. Bassendine. Section II: Bile Acid Therapy. 5. Optimum Dose of
UDCA in Primary Biliary Cirrhosis (PBC); A. Verma. 6. Ursodeoxycholic Acid
- An Immunomodulator in Primary Biliary Cirrhosis? A.G. Lim, et al.
Section III: Clinical Trials. 7. Primary Biliary Cirrhosis: Long-Term
Management with Ursodeoxycholic Acid; J. Heathcote. 8. Management of
Patients with Primary Schlerosing Cholangitis; A. Stiehl. 9. Genetic
Aspects; R. Thompson. 10. Congenital Defects in Bile Acid Synthesis Cause A
Spectrum of Diseases Manifest as Severe Cholestasis, Neurological Disease,
and Fat-Soluble Vitamin Malabsorption; K.D.R. Setchell. 11. Cystic Fibrosis
of the Liver; C. Colombo. 12. Canalicular Secretion of Lysyl-fluorescein
Bile Acids in 17beta-estradiol Glucuronide (17betaEG) Induced Cholestasis:
Protective Effect of S-andenosyl-L-methionine (SAMe); P. Milkiewicz.
Section IV: Alcoholic and Other Liver Diseases. 13. Ethanol Metabolism; T.
Peters. 14. Alcohol Abuse and Abstinence; H. Ghodse. 15. Pathogenesis of
Alchoholic Liver Disease; C.S. Lieber. 16. Clinical Aspects of Alcoholic
Liver Disease; R. Williams. Section V: Bile Acid Therapy. 17. Effect on
Liver Function; P. Hayes. 18. Fibrosis Markers and Ursodeoxycholic Acid;
J.M.C. Stenner. 19. Urdodeoxycholic Acid for Treatment of Chronic Hepatitis
C: An `Interferon Sparing' Effect; A. Lanzini. Section VI: Cholesterol
Gallstone Disease. 20. Pathogenesis of Cholesterol Gallstone Disease: Role
of the Liver; M.C. Carey. 21. Pathogenesis of Gallstones: Events in Bile;
T. Gilat. 22. Role of the Gallbladder in the Pathogenesis of Gallstone
Disease; R.P. Jazrawi, et al. 23. The Role of the Large Intestine in
Cholesterol Gallstone Formation; K.W. Heaton. 24. The Octreotide Model;
R.H. Dowling. Section VII: Therapy. 25. Oral Bile Acid Therapy; E. Roda.
26. Cholesterol Solvents for Topical Gallstone Dissolution; U. Leuschner.
27. Mechanisms of Dissolution of Cholesterol Gallstones; H.A. Ahmed. 28.
Extracorporeal Shock-wave Lithotripsy of Gallstones; G.H. Sauter. 29.
Management of Gallstone Recurrence; T.C. Northfield. 30. Laparoscopic
Cholecystectomy; A. Johnson. 31. Comparison of UDCA With Combination
Therapy of UDCA Plus CDCA on Gallstone Dissolution: A Randomised
Multicentre Trial; M.L. Petroni. Section VIII: Other Conditions. 32. Role
of Bile Acids in Colonic Neoplasia: Experimental Animal Studies; C.A.
Einarsson. 33. Role of Bile Acids in Colonic Neoplasia &endash; Human
Studies; M. Stellini. Section IX: Chronic Pancreatitis. 34. Role of Bile
Acids in Pancratic Steatorrhea; P. Zentler-Munro. 35. Impaired Uptake of
Long-chain Fatty Acids Contributes to Fat Malabsorption in Paediatric
Patients with Cystic Fibrosis; H.J. Verkade. 36. Bile Acid Science
(Cholanology) at the Dawn of a New Millennium: Past Progress and Challenges
for the Future; A.F. Hofmann. Index.
Preface. List of Contributors. 1. Introduction; T.C. Northfield. Section I:
Cholestatic Liver Disease: Physiology, Pathogenesis and Epidemiology. 2.
Cellular and Molecular Mechanisms of Bile Salt Transport in Health and
Disease; J.L. Boyer. 3. Biochemical Aspects; J. Reichen. 4. Immunological
Aspects; M.F. Bassendine. Section II: Bile Acid Therapy. 5. Optimum Dose of
UDCA in Primary Biliary Cirrhosis (PBC); A. Verma. 6. Ursodeoxycholic Acid
- An Immunomodulator in Primary Biliary Cirrhosis? A.G. Lim, et al.
Section III: Clinical Trials. 7. Primary Biliary Cirrhosis: Long-Term
Management with Ursodeoxycholic Acid; J. Heathcote. 8. Management of
Patients with Primary Schlerosing Cholangitis; A. Stiehl. 9. Genetic
Aspects; R. Thompson. 10. Congenital Defects in Bile Acid Synthesis Cause A
Spectrum of Diseases Manifest as Severe Cholestasis, Neurological Disease,
and Fat-Soluble Vitamin Malabsorption; K.D.R. Setchell. 11. Cystic Fibrosis
of the Liver; C. Colombo. 12. Canalicular Secretion of Lysyl-fluorescein
Bile Acids in 17beta-estradiol Glucuronide (17betaEG) Induced Cholestasis:
Protective Effect of S-andenosyl-L-methionine (SAMe); P. Milkiewicz.
Section IV: Alcoholic and Other Liver Diseases. 13. Ethanol Metabolism; T.
Peters. 14. Alcohol Abuse and Abstinence; H. Ghodse. 15. Pathogenesis of
Alchoholic Liver Disease; C.S. Lieber. 16. Clinical Aspects of Alcoholic
Liver Disease; R. Williams. Section V: Bile Acid Therapy. 17. Effect on
Liver Function; P. Hayes. 18. Fibrosis Markers and Ursodeoxycholic Acid;
J.M.C. Stenner. 19. Urdodeoxycholic Acid for Treatment of Chronic Hepatitis
C: An `Interferon Sparing' Effect; A. Lanzini. Section VI: Cholesterol
Gallstone Disease. 20. Pathogenesis of Cholesterol Gallstone Disease: Role
of the Liver; M.C. Carey. 21. Pathogenesis of Gallstones: Events in Bile;
T. Gilat. 22. Role of the Gallbladder in the Pathogenesis of Gallstone
Disease; R.P. Jazrawi, et al. 23. The Role of the Large Intestine in
Cholesterol Gallstone Formation; K.W. Heaton. 24. The Octreotide Model;
R.H. Dowling. Section VII: Therapy. 25. Oral Bile Acid Therapy; E. Roda.
26. Cholesterol Solvents for Topical Gallstone Dissolution; U. Leuschner.
27. Mechanisms of Dissolution of Cholesterol Gallstones; H.A. Ahmed. 28.
Extracorporeal Shock-wave Lithotripsy of Gallstones; G.H. Sauter. 29.
Management of Gallstone Recurrence; T.C. Northfield. 30. Laparoscopic
Cholecystectomy; A. Johnson. 31. Comparison of UDCA With Combination
Therapy of UDCA Plus CDCA on Gallstone Dissolution: A Randomised
Multicentre Trial; M.L. Petroni. Section VIII: Other Conditions. 32. Role
of Bile Acids in Colonic Neoplasia: Experimental Animal Studies; C.A.
Einarsson. 33. Role of Bile Acids in Colonic Neoplasia &endash; Human
Studies; M. Stellini. Section IX: Chronic Pancreatitis. 34. Role of Bile
Acids in Pancratic Steatorrhea; P. Zentler-Munro. 35. Impaired Uptake of
Long-chain Fatty Acids Contributes to Fat Malabsorption in Paediatric
Patients with Cystic Fibrosis; H.J. Verkade. 36. Bile Acid Science
(Cholanology) at the Dawn of a New Millennium: Past Progress and Challenges
for the Future; A.F. Hofmann. Index.
Cholestatic Liver Disease: Physiology, Pathogenesis and Epidemiology. 2.
Cellular and Molecular Mechanisms of Bile Salt Transport in Health and
Disease; J.L. Boyer. 3. Biochemical Aspects; J. Reichen. 4. Immunological
Aspects; M.F. Bassendine. Section II: Bile Acid Therapy. 5. Optimum Dose of
UDCA in Primary Biliary Cirrhosis (PBC); A. Verma. 6. Ursodeoxycholic Acid
- An Immunomodulator in Primary Biliary Cirrhosis? A.G. Lim, et al.
Section III: Clinical Trials. 7. Primary Biliary Cirrhosis: Long-Term
Management with Ursodeoxycholic Acid; J. Heathcote. 8. Management of
Patients with Primary Schlerosing Cholangitis; A. Stiehl. 9. Genetic
Aspects; R. Thompson. 10. Congenital Defects in Bile Acid Synthesis Cause A
Spectrum of Diseases Manifest as Severe Cholestasis, Neurological Disease,
and Fat-Soluble Vitamin Malabsorption; K.D.R. Setchell. 11. Cystic Fibrosis
of the Liver; C. Colombo. 12. Canalicular Secretion of Lysyl-fluorescein
Bile Acids in 17beta-estradiol Glucuronide (17betaEG) Induced Cholestasis:
Protective Effect of S-andenosyl-L-methionine (SAMe); P. Milkiewicz.
Section IV: Alcoholic and Other Liver Diseases. 13. Ethanol Metabolism; T.
Peters. 14. Alcohol Abuse and Abstinence; H. Ghodse. 15. Pathogenesis of
Alchoholic Liver Disease; C.S. Lieber. 16. Clinical Aspects of Alcoholic
Liver Disease; R. Williams. Section V: Bile Acid Therapy. 17. Effect on
Liver Function; P. Hayes. 18. Fibrosis Markers and Ursodeoxycholic Acid;
J.M.C. Stenner. 19. Urdodeoxycholic Acid for Treatment of Chronic Hepatitis
C: An `Interferon Sparing' Effect; A. Lanzini. Section VI: Cholesterol
Gallstone Disease. 20. Pathogenesis of Cholesterol Gallstone Disease: Role
of the Liver; M.C. Carey. 21. Pathogenesis of Gallstones: Events in Bile;
T. Gilat. 22. Role of the Gallbladder in the Pathogenesis of Gallstone
Disease; R.P. Jazrawi, et al. 23. The Role of the Large Intestine in
Cholesterol Gallstone Formation; K.W. Heaton. 24. The Octreotide Model;
R.H. Dowling. Section VII: Therapy. 25. Oral Bile Acid Therapy; E. Roda.
26. Cholesterol Solvents for Topical Gallstone Dissolution; U. Leuschner.
27. Mechanisms of Dissolution of Cholesterol Gallstones; H.A. Ahmed. 28.
Extracorporeal Shock-wave Lithotripsy of Gallstones; G.H. Sauter. 29.
Management of Gallstone Recurrence; T.C. Northfield. 30. Laparoscopic
Cholecystectomy; A. Johnson. 31. Comparison of UDCA With Combination
Therapy of UDCA Plus CDCA on Gallstone Dissolution: A Randomised
Multicentre Trial; M.L. Petroni. Section VIII: Other Conditions. 32. Role
of Bile Acids in Colonic Neoplasia: Experimental Animal Studies; C.A.
Einarsson. 33. Role of Bile Acids in Colonic Neoplasia &endash; Human
Studies; M. Stellini. Section IX: Chronic Pancreatitis. 34. Role of Bile
Acids in Pancratic Steatorrhea; P. Zentler-Munro. 35. Impaired Uptake of
Long-chain Fatty Acids Contributes to Fat Malabsorption in Paediatric
Patients with Cystic Fibrosis; H.J. Verkade. 36. Bile Acid Science
(Cholanology) at the Dawn of a New Millennium: Past Progress and Challenges
for the Future; A.F. Hofmann. Index.